Watch on StartUp Health TV
Summary
The noninvasive continuous glucose monitor has been called the holy grail of diabetes technology for decades. SynchNeuro thinks the answer has been hiding behind your ear the whole time.
In this Health Moonshot Update conversation, StartUp Health co-founder Unity Stoakes sits down with Casey Halpern, MD, Founder & Chairman of SynchNeuro, to discuss the company's working prototype, its IRB-approved clinical study launching in weeks, and a commercial target of late 2027 to early 2028. They also dig into the platform's daily glucose stability score -- a sleep-powered forecast for your metabolism that updates every five minutes throughout the day -- and what it could mean for the 40 to 50 million Americans with prediabetes who are motivated to act but starved of tools.
Today’s Sponsor
14.6% Net Returns After Losses. 8.9% High Yield. 6.1% Leveraged Loans. 4.5% Investment Grade.
For the twelve months ending March 31, 2026, Percent's ABS deals returned 14.6% net after losses — vs. 8.9% HY bonds, 6.1% leveraged loans, 4.5% investment grade.†
Private credit belongs in the credit sleeve. Against those benchmarks, the gap is hard to ignore. 17.0% current weighted average coupon rate.† 93.5% of performing deals pay monthly fixed-rate coupons. Starting at $500.
Alternative investments are speculative. †Past performance is not indicative of future results. Benchmark indices shown for market context only and are not directly comparable to Percent's performance. Terms apply.
Highlights
🧠 SynchNeuro is using brain activity as a new source of metabolic health data, linking EEG signals to glucose swings, sleep, stress, heart rate, and physical activity.
🩸 The company is building a non-invasive glucose monitor that sits discreetly behind the ear, avoiding needles, incisions, and traditional invasive CGMs.
🤖 AI makes the innovation possible by helping decode noisy EEG signals and extract meaningful patterns from long-term, 24/7 data.
🌙 Sleep is a major focus because poor sleep can lead to higher morning blood sugar and worse metabolic outcomes.
📈 SynchNeuro aims to give users a daily “forecast” that predicts potential glucose spikes and offers personalized guidance before problems happen.
🍽️ The platform may include automated food diary tools and personalized nutrition insights to help users understand which foods trigger glucose spikes.
🧪 SynchNeuro has a working prototype and is preparing for algorithm training through an IRB-approved human study.
✅ Early data showed accuracy nearly matching Dexcom with about 20 subjects, suggesting strong signal potential from the brain.
🏥 The first target population includes people with prediabetes and Type 2 diabetes who want affordable, proactive tools to avoid disease progression.
🚀 The company is targeting a potential commercial launch in late 2027 or early 2028, pending fundraising, validation, and FDA clearance.
Are you ready to tell YOUR story?
Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is available to StartUp Health Members. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit.
👉 Learn more and join today.
